Metformin The Benefits of Metformin for Reducing COVID-19 Severity
As the world continues to study COVID-19, researchers are discovering that metformin, a medication commonly used to treat diabetes, might offer some unexpected benefits. Recent studies suggest that metformin can be used for reducing COVID-19 severity. It could help lower the risk of serious illness and even long-term complications, like long COVID. In a recent Lancet study, people who took metformin during the early stages of COVID-19 were 41% less likely to develop long COVID compared to those who didn’t.
I had previously written about metformin before regarding its benefits to patients with Diabetes, pre-diabetes, PCOS and other long term conditions. In this post, I will highlight what metformin does and how it may play a role in reducing the severity of COVID-19.
How Metformin Can Help Reduce COVID-19 Severity
Metformin is widely used to help people with type 2 diabetes control their blood sugar, but it also has anti-inflammatory effects that have caught the attention of researchers. A recent study published in The Lancet found that using metformin for reducing COVID-19 severity could prevent long COVID. In this study, people who took metformin during the early stages of COVID-19 were 41% less likely to develop long COVID compared to those who didn’t.
This is likely due to metformin’s ability to reduce inflammation in the body, which can help prevent the “cytokine storm” that leads to severe COVID-19 symptoms, like difficulty breathing and pneumonia.
Scientific Evidence Supporting Metformin for Reducing COVID-19 Severity
Another review from the National Library of Medicine explored how metformin for reducing COVID-19 severity might be beneficial. The review looked at several clinical trials and found that metformin not only helped people with diabetes but also reduced severe symptoms in non-diabetic individuals. This suggests that metformin’s benefits may extend beyond blood sugar control.
The review pointed out that metformin helps lower levels of inflammatory chemicals, like interleukin-6 (IL-6), which can lead to serious complications in COVID-19. By reducing these inflammation levels, metformin could lower the need for hospitalization and improve survival rates in people with COVID-19.
What This Means for COVID-19 Treatment
Using metformin for reducing COVID-19 severity could open new doors in the way we manage the disease. While vaccines and antiviral drugs are still crucial, metformin could become an affordable and widely available tool, especially for people with pre-existing conditions like diabetes or obesity. It’s safe, affordable, and has been around for decades, making it a promising candidate for future COVID-19 treatments.
Though more research is needed, the current evidence suggests metformin could help prevent severe symptoms and long-term complications from COVID-19.
Conclusion
Metformin is showing great promise as a tool for reducing the severity of COVID-19. Metofmin has anti-inflammatory properties and ability to regulate the immune response. This makes it a strong candidate for managing both immediate and long-term effects of the virus. As more research is conducted, we may see metformin for reducing COVID-19 severity become a standard part of COVID-19 treatment. This is especially true for those at higher risk of severe illness. However, it’s always important to speak with a healthcare provider before starting any new medication, especially for COVID-19.
References:
